NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics, Inc. (NASDAQ:CYTK) released its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.06. The biopharmaceutical company earned $6.06 million during the quarter, compared to analyst estimates of $7.80 million. Cytokinetics had a negative net margin of 378.70% and a negative return on equity of 10,351.99%. View Cytokinetics' Earnings History.

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Cytokinetics.

6 brokerages have issued twelve-month price targets for Cytokinetics' shares. Their forecasts range from $16.00 to $26.00. On average, they anticipate Cytokinetics' stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 77.1% from the stock's current price. View Analyst Price Targets for Cytokinetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

News articles about CYTK stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cytokinetics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Cytokinetics.

Cytokinetics saw a increase in short interest in December. As of December 31st, there was short interest totalling 9,400,000 shares, an increase of 6.7% from the December 15th total of 8,810,000 shares. Based on an average daily volume of 840,600 shares, the days-to-cover ratio is presently 11.2 days. Currently, 17.3% of the shares of the stock are sold short. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), Karuna Therapeutics (KRTX), Zogenix (ZGNX), ArQule (ARQL), Arena Pharmaceuticals (ARNA), Epizyme (EPZM), Ra Pharmaceuticals (RARX), Synthorx (THOR), Aimmune Therapeutics (AIMT), Aurinia Pharmaceuticals (AUPH), Turning Point Therapeutics (TPTX), Xencor (XNCR), Eidos Therapeutics (EIDX) and Principia Biopharma (PRNB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (amgn), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), Synergy Pharmaceuticals (SGYP) and TG Therapeutics (TGTX).

Cytokinetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Mirador Capital Partners LP (0.17%), Louisiana State Employees Retirement System (0.03%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View Institutional Ownership Trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

CYTK stock was acquired by a variety of institutional investors in the last quarter, including Mirador Capital Partners LP and Nisa Investment Advisors LLC. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $12.14.

Cytokinetics has a market capitalization of $717.26 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.

The official website for Cytokinetics is http://www.cytokinetics.com/.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]